Pharmacist-led intervention to improve blood pressure control in hypertensive patients

Effect of a Pharmacist-led Multifaceted Intervention on Treatment Outcomes in Hypertensive Patients: a Cluster Randomised Clinical Trial

This study tests whether a pharmacist-led program that includes education and support can help people with high blood pressure manage their condition better than just standard health advice.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 1200 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Xijing Hospital (Academic / other)
• Locations: 1 site (Xi'an, Shaanxi)
• Trial ID: NCT06558877 on ClinicalTrials.gov

What this trial studies

This cluster randomized controlled trial aims to evaluate the effectiveness of a pharmacist-led multifaceted intervention on poorly controlled hypertensive patients across eight tertiary hospitals in China. The study will enroll 800 participants, randomly assigning hospitals to either an intervention or control group. The intervention includes health education, home blood pressure telemonitoring, medication consultation, reminders, and individualized medication regimens, while the control group receives standard health education. Outcomes will be assessed at multiple time points to measure changes in blood pressure control, adherence to medication, and cardiovascular disease risk.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-80 with poorly controlled hypertension who are currently on antihypertensive medication.

Not a fit: Patients with well-controlled hypertension or those unable to use smartphones and WeChat may not benefit from this study.

Why it matters

Potential benefit: If successful, this intervention could significantly improve blood pressure management and reduce cardiovascular risks for patients with hypertension.

How similar studies have performed: Previous studies have shown that pharmacist-led interventions can improve medication adherence and health outcomes in hypertensive patients, indicating potential success for this approach.

Eligibility criteria

Inclusion Criteria (subjects must meet all of the following criteria to be included):

* 1\) age 18-80 years;
* 2\) patients with hypertension (diagnostic criteria: defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg according to the "Guidelines for the prevention and treatment of hypertension in China in 2023", based on the blood pressure measurement of three times on different days), who are currently taking anti-hypertensive medication and are judged by the research physician to have poor blood pressure control;
* 3\) able to use smartphones and WeChat proficiently, and can communicate and upload pictures proficiently;
* 4\) able to take care of yourself and communicate normally, and willing to cooperate with the research physician to complete the study and follow-up;
* 5\) permanent residents of the city where the center is located;
* 6\) voluntarily participate and sign the informed consent form

Exclusion Criteria(subjects will be excluded if they meet any of the following criteria):

* 1\) patients with advanced disease (such as patients undergoing dialysis or liver failure), or with a life expectancy of less than 2 years as determined by the research physician;
* 2\) combined with psychiatric disease, cognitive impairment, communication disorder, or inability to cooperate with the researchers;
* 3\) combined with cerebrovascular disease, stroke, severe liver and kidney dysfunction, severe heart failure, cancer and history of organ transplantation, etc.;
* 4\) patients who are pregnant, breastfeeding, or planning to conceive in the next 2 years.

Where this trial is running

Xi'an, Shaanxi

• Xijing hospital — Xi'an, Shaanxi, China (Recruiting)

Study contacts

• Study coordinator: Qianqian Dong, Doctor

Conditions Hypertension